Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

Other analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. HC Wainwright reduced their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Canaccord Genuity Group began coverage on Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $48.36 on Friday. The company has a market cap of $3.44 billion, a PE ratio of -55.59 and a beta of -1.50. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90. The firm has a 50 day simple moving average of $46.69 and a 200 day simple moving average of $54.94.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, equities analysts predict that Structure Therapeutics will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in GPCR. CWM LLC increased its holdings in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares during the period. HighTower Advisors LLC lifted its stake in shares of Structure Therapeutics by 3.6% in the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. State of Wyoming grew its position in Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after buying an additional 403 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after buying an additional 444 shares in the last quarter. Finally, Assetmark Inc. increased its stake in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.